SubsidieMeestersFunctional chemical reprogramming of cancer cells to induce antitumor immunity
The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.
Projectdetails
THE CHALLENGE
Immunotherapy has revolutionized cancer treatment, but most patients do not respond due to immune evasion mechanisms, including heterogeneity and lack of tumor antigen presentation. Moreover, these therapies have met limited success in the treatment of solid tumors and are frequently associated with severe adverse effects.
RADICAL VISION
The radical vision of the RESYNC consortium is to revolutionize cancer immunotherapy through small-molecule (SM)-based reprogramming of cancer cells into immunogenic (neo)antigen-presenting dendritic cells type 1 (cDC1) to elicit a personalized anti-tumor immunity.
Cell reprogramming will be coupled with nanoparticle formulations enabling safe, low-cost, and efficient systemic targeting of disseminated tumors. The proposed platform will enable breakthrough innovations in the cellular reprogramming-based therapeutics space and have a broad and disruptive effect on the immune-oncology therapeutics scientific field and market.
With a complementary consortium, we expect to achieve proof-of-concept for chemical cDC1 reprogramming by the end of the project (2026).
IMPACT
This approach will for the first time harness the full potential of cellular reprogramming to induce immunity against tumor antigens with the tractability of systemic delivery of cDC1-inducing SMs.
This project will result in next-generation platforms for in vivo reprogramming and cell-targeted delivery of SMs with:
- High cell specificity
- Low price
- Improved safety
SM-mediated antigen presentation will be combined with immune checkpoint blockade, enabling immunotherapy in all patients. Ultimately, this project will set the stage for a new era of personalized, off-the-shelf cancer immunotherapies.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.966.695 |
| Totale projectbegroting | € 2.966.695 |
Tijdlijn
| Startdatum | 1-1-2024 |
| Einddatum | 31-12-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- LUNDS UNIVERSITETpenvoerder
- ASGARD THERAPEUTICS AB
- POLITECNICO DI TORINO
- UNIVERSITATEA BABES BOLYAI
- USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I.
- KAROLINSKA INSTITUTET
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A multiplexed biomimetic imaging platform for assessing single cell plasticity (Plastomics) and scoring of tumour malignancyThe PLAST_CELL project aims to develop a microfluidics-based imaging platform to quantify cancer cell plasticity, enhancing diagnosis and treatment of metastasis and therapy resistance. | EIC Pathfinder | € 2.982.792 | 2022 | Details |
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation. | EIC Pathfinder | € 2.996.550 | 2022 | Details |
Smart Electronic Olfaction for Body Odor DiagnosticsSMELLODI aims to digitize and synthesize olfactory information for remote disease diagnostics and assist individuals with olfactory disorders using advanced sensor technology and machine learning. | EIC Pathfinder | € 3.263.781 | 2022 | Details |
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images. | EIC Pathfinder | € 2.744.300 | 2022 | Details |
A multiplexed biomimetic imaging platform for assessing single cell plasticity (Plastomics) and scoring of tumour malignancy
The PLAST_CELL project aims to develop a microfluidics-based imaging platform to quantify cancer cell plasticity, enhancing diagnosis and treatment of metastasis and therapy resistance.
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"
The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.
Smart Electronic Olfaction for Body Odor Diagnostics
SMELLODI aims to digitize and synthesize olfactory information for remote disease diagnostics and assist individuals with olfactory disorders using advanced sensor technology and machine learning.
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.
The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Polyclonal anti-tumor immunity by engineered human T cellsThis project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes. | ERC STG | € 1.812.500 | 2022 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC COG | € 1.993.875 | 2023 | Details |
Developing novel single-cell technologies to model and perturb intra-tumor interactions and signaling – an innovation program for the next generation of immunotherapiesThe TROJAN-Cell project aims to engineer immune responses against tumors by understanding immune-suppressive mechanisms in the tumor microenvironment using advanced single-cell technologies. | ERC ADG | € 2.500.000 | 2022 | Details |
Modular Targeted Nanoplatform for Immune Cell Regulation and TherapyImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative. | ERC POC | € 150.000 | 2023 | Details |
Polyclonal anti-tumor immunity by engineered human T cells
This project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes.
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
Developing novel single-cell technologies to model and perturb intra-tumor interactions and signaling – an innovation program for the next generation of immunotherapies
The TROJAN-Cell project aims to engineer immune responses against tumors by understanding immune-suppressive mechanisms in the tumor microenvironment using advanced single-cell technologies.
Modular Targeted Nanoplatform for Immune Cell Regulation and Therapy
ImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative.